Germany CAR-T Cell Therapy Market to Grow with a CAGR of 65.13% through 2028
Rising prevalence of hematological malignancies are expected
to drive the Germany CAR-T Cell Therapy Market growth in the forecast period,
2024-2028.
According to TechSci Research report, “CAR-T Cell
Therapy Market – Germany Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Germany CAR-T Cell Therapy Market
stood at USD 219.83 million in 2022 and is anticipated to grow with a CAGR of 65.13%
in the forecast period, 2024-2028. The Germany CAR-T cell therapy market is
experiencing substantial growth, driven by a combination of factors that have
propelled this innovative field of cancer treatment to the forefront of medical
research and healthcare delivery. Chimeric Antigen Receptor T-cell therapy, or
CAR-T cell therapy, represents a groundbreaking approach to cancer treatment,
offering new hope to patients with refractory or relapsed malignancies. Germany's
healthcare infrastructure is renowned for its quality and accessibility. The
country boasts an extensive network of well-equipped hospitals, clinics, and
research facilities, making it an ideal environment for the development and
implementation of cutting-edge medical therapies like CAR-T cell therapy. This
robust healthcare system ensures that CAR-T therapies can be effectively
administered and monitored, enhancing patient outcomes and safety. Germany's
academic and research institutions have a long-standing tradition of excellence
in medical and biotechnological research. Collaborations between universities,
research centers, and biopharmaceutical companies have been instrumental in
advancing CAR-T cell therapy in the country. The strong ties between academic
research and clinical application facilitate rapid developments and clinical
trials, thereby accelerating the adoption of CAR-T therapies. Germany is home to a thriving pharmaceutical
and biotechnology industry, which plays a pivotal role in the advancement of
CAR-T cell therapies. Leading pharmaceutical companies have invested heavily in
CAR-T research and development, often partnering with academic institutions and
smaller biotech firms to bring innovative therapies to market. The synergy
between these sectors has contributed significantly to the rapid growth of the
CAR-T cell therapy market.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Germany CAR-T Cell Therapy Market.”
Germany has emerged as a popular destination for
dental tourism, attracting patients from across Europe and beyond. The
country's high-quality dental care, well-trained professionals, and advanced
dental facilities have made it an attractive choice for individuals seeking
dental treatments. Dental tourism has resulted in a higher influx of patients,
leading to increased demand for CAR-T Cell Therapy in German dental clinics and
hospitals. The Germany CAR-T Cell Therapy Market is segmented
into Product Type, Tumor Type, Treatment Type, Targeted Antigen, End User, Regional Distribution,
And Company. Based on the Tumor Type, Hematological Malignancies emerged as the
dominant segment in the Germany CAR-T Cell Therapy Market in 2022. CAR-T cell
therapies have demonstrated remarkable success in treating hematological
malignancies. Patients who have undergone CAR-T therapy have experienced
significant remissions and, in some cases, long-term disease-free survival.
This clinical success has created a strong demand for these innovative
therapies among patients and healthcare providers. Germany, like many developed
nations, has a relatively high incidence of hematological malignancies. The
prevalence of these cancers necessitates advanced and effective treatment
options to address the growing patient population. Hematological malignancies
can be particularly aggressive and difficult to treat using traditional methods
such as chemotherapy and radiation therapy. CAR-T cell therapy offers a
promising alternative, especially for patients who have not responded to or
have relapsed after standard treatments.
Based on the indication, the Diffused Large B-cell
Lymphoma (DLBCL) segment emerged as the dominant player in the Germany CAR-T
Cell Therapy Market in 2022. DLBCL is the most common type of non-Hodgkin
lymphoma, and its incidence rates have been rising in Germany and worldwide.
This increased prevalence has created a substantial patient population in need
of effective treatment options. DLBCL is known for its aggressive nature and
resistance to traditional therapies like chemotherapy and radiation. As a result,
patients often require innovative and more targeted treatment strategies like
CAR-T cell therapy.CAR-T cell therapy has demonstrated remarkable clinical
success in treating DLBCL. Many patients who have received CAR-T treatments
have experienced substantial remissions and improved quality of life,
particularly when other treatments have failed.
Based on the Targeted Antigen, the CD 19 segment
emerged as the dominant player in the Germany CAR-T Cell Therapy Market in 2022.
CD19 is
prominently expressed in various B-cell malignancies, including B-cell acute
lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphomas. These cancers are
relatively common in Germany, driving the need for targeted CD19-specific
therapies. CD19-targeted CAR-T cell therapies have demonstrated impressive
clinical success, particularly in treating B-cell malignancies. Patients who
receive CD19 CAR-T treatment often experience significant remissions and
prolonged disease-free survival, making it a highly sought-after therapy. In
many cases, patients with CD19-positive malignancies have limited treatment
options, especially if standard therapies have failed or if they have
experienced relapse. CD19 CAR-T therapy offers a novel approach to treatment
for these patients. Germany is a hub for cutting-edge research in the
field of CAR-T therapy, and CD19-based therapies have been a central focus of
this research. Collaborations between academic institutions and the
biopharmaceutical industry have led to the rapid development and deployment of
CD19 CAR-T therapies in clinical practice.
Western region emerged as the dominant player in the
Germany CAR-T Cell Therapy Market in 2022, holding the largest market share.
Western Germany is home to many research and development centers and
pharmaceutical companies actively involved in CAR-T cell therapy research and
clinical trials. These institutions drive innovation and facilitate the
development of CAR-T treatments. The excellent transportation and logistical
infrastructure in Western Germany make it easier for patients to access medical
centers, including those offering CAR-T therapy. The convenience of travel and
accessibility encourages patients to seek treatment in this region.
The Western region boasts state-of-the-art healthcare
facilities, world-class hospitals, and renowned medical institutions. These
institutions are more likely to adopt and offer advanced treatments, making
CAR-T cell therapy more accessible to patients. Western Germany is economically
prosperous, with a strong industrial and financial base. This prosperity often
leads to greater investment in healthcare, research, and technology,
facilitating the adoption of cutting-edge therapies like CAR-T.
Major companies operating in Germany CAR-T Cell
Therapy Market are:
- Gilead Sciences, Inc
- Novartis International AG
- Bristol Myers Squibb Co.
- AbbVie Inc.
- Cellectis SA
- Amgen Inc
- Pfizer Inc.
- Merck & Co. Inc.
- Intellia Therapeutics Inc.
- Poseida Therapeutics Inc
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Germany
CAR-T cell therapy market is poised for significant growth in the coming
years., the rising incidence of hematological malignancies and the expanding
applications of CAR-T therapy to treat various cancer types create a
substantial patient pool. The clinical success of CAR-T therapies, particularly
in treating aggressive and refractory cancers, has bolstered their adoption and
increased patient demand. Government support and reimbursement mechanisms in
Germany provide an enabling environment for the adoption of innovative
therapies. Strong collaborations between academic institutions, research
centers, and the biopharmaceutical industry drive ongoing advancements in CAR-T
technology.” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Germany CAR-T Cell Therapy Market Segmented
Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel),
Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel),
Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological
Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma
(DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle
Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination
Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen),
Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical
Centers, Others) Region and Competition, Opportunity, and Forecast, 2018-2028”, has evaluated
the future growth potential of Germany CAR-T Cell Therapy Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Germany CAR-T Cell Therapy Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com